Results 31 to 40 of about 51,116 (225)

Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]

, 2016
Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva, Desai, Akshay S., Jhund, Pardeep S., Kristensen, Søren L., Lefkowitz, Martin P., Martinez, Felipe, McMurray, John J.V., Merkely, Bela, Packer, Milton, Preiss, David, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Squire, Iain, Starling, Randall C., Swedberg, Karl, Zile, Michael R.   +17 more
core   +1 more source

Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study

Circulation: Heart Failure, 2022
Background: Sacubitril/valsartan was demonstrated to reduce hospitalization rate and mortality in patients with heart failure with reduced ejection fraction.
F. Fusco, G. Scognamiglio, A. Merola, A. Iannuzzi, M. Palma, N. Grimaldi, B. Sarubbi   +6 more
semanticscholar   +1 more source

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]

, 2017
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan, Desai, Akshay S., Dukát, Andrej, Jhund, Pardeep S., Kristensen, Søren L., Køber, Lars, Lefkowitz, Martin P., McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Prescott, Margaret F., Ramires, Felix, Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl   +16 more
core   +3 more sources

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling

Frontiers in Pharmacology, 2022
Cardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease.
N. Mustafa, Juriyati Jalil, S. Zainalabidin, M. Saleh, A. Y. Asmadi, Y. Kamisah   +5 more
semanticscholar   +1 more source

Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways

Frontiers in Pharmacology
Background: Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a common respiratory disease characterized by persistent hypoxemia and an uncontrolled inflammatory response.
Mi Zhou, Ling Meng, Qinke He, Chunguang Ren, Changyi Li   +4 more
semanticscholar   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Cardiovascular Diabetology, 2022
Background Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.
M. Wijkman, B. Claggett, M. Vaduganathan, J. Cunningham, R. Rørth, Alice Jackson, M. Packer, M. Zile, J. Rouleau, K. Swedberg, M. Lefkowitz, Sanjiv J. Shah, M. Pfeffer, J. McMurray, S. Solomon   +14 more
semanticscholar   +1 more source

Non-adherence to cardiovascular pharmacotherapy in Iraq assessed using 8-items Morisky questionnaire and analysis of dried blood spot samples [PDF]

, 2019
open access journalThe study evaluated the non-adherence to selected cardiovascular medications, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, simvastatin and valsartan in Iraqi patients by applying a standardized Morisky questionnaire (8 ...
Alalaqi, Ahmed, Lawson, Graham, Obaid, Yaseen, Tanna, Sangeeta   +3 more
core   +1 more source

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.

Journal of the American College of Cardiology
BACKGROUND The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described.
David A. Morrow, Eric J. Velazquez, A. Desai, A. DeVore, S. Lepage, Jeon-Gun Park, K. Sharma, Scott D. Solomon, Randall C. Starling, Jonathan H. Ward, Kristin M. Williamson, S. Zieroth, Adrian F. Hernandez, R. Mentz, Eugene Braunwald   +14 more
semanticscholar   +1 more source

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig, Albrecht, Diego, Bremerich, Jens, Delles, Christian, Freyhardt, Patrick, Heye, Tobias, Hrabak-Paar, Maja, Janka, Rolf, Keicher, Christian, Khder, Yasser, Langenickel, Thomas, Mayr, Michael, Ott, Christian, Schmieder, Roland E., Wagner, Frank, Yates, Denise   +15 more
core   +1 more source